Literature DB >> 8819196

Experimental model for the study by chemiluminescence of the activation of isolated equine leucocytes.

H Benbarek1, G Deby-Dupont, C Deby, I Caudron, M Mathy-Hartert, M Lamy, D Serteyn.   

Abstract

The activation of human polymorphonuclear leucocytes (the respiratory burst) can be studied by measuring their chemiluminescent response. This technique was adapted to equine leucocytes to investigate the effects of cell number, activator concentration, enhancers of chemiluminescence, pH, temperature and inhibitors. Leucocytes were isolated from citrated blood from healthy horses and chemiluminescence was measured with a Bio-Orbit luminometer sensitive to 900 nm light. The optimal cell density for the maximal chemiluminescent response ranged from 10(6) to 10(7) leucocytes 600 microliters-1. Chemiluminescence increased as a function of temperature, and the concentrations of luminol, lucigenin and phorbol myristate acetate (PMA), and was pH related (optimal pH value = 8.0 for lucigenin and 8.5 for luminol). The inhibition of chemiluminescence by 5 x 10(-5) M azide was 88 per cent for luminol and 37 per cent for lucigenin. Superoxide dismutase (100 IU) totally inhibited the chemiluminescence response. Approximately 30 per cent variability in chemiluminescence was observed under the same assay conditions, depending on the origin of the leucocytes. Based on these results, the conditions selected for the measurement of equine leucocyte chemiluminescence were: 10(6) to 10(7) leucocytes 600 microliters-1, 1 x 10(-6)M PMA, 1 mM luminol or 0.4 mM lucigenin, physiological pH (7.4) and physiological temperature (37.8 degrees C). These conditions were similar to those used for measuring the chemiluminescent response of human leucocytes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8819196     DOI: 10.1016/s0034-5288(96)90112-5

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  7 in total

1.  Failure of lipopolysaccharides to directly trigger the chemiluminescence response of isolated equine polymorphonuclear leukocytes.

Authors:  H Benbarek; G Deby-Dupont; I Caudron; C Deby; M Lamy; D Serteyn
Journal:  Vet Res Commun       Date:  1997-10       Impact factor: 2.459

2.  Modulatory effects of non-steroidal anti-inflammatory drugs on the luminol and lucigenin amplified chemiluminescence of equine neutrophils.

Authors:  H Benbarek; A Ayad; G Deby-Dupont; L Boukraa; D Serteyn
Journal:  Vet Res Commun       Date:  2011-10-21       Impact factor: 2.459

3.  Avenanthramide supplementation attenuates eccentric exercise-inflicted blood inflammatory markers in women.

Authors:  Ryan T Koenig; Jonathan R Dickman; Choung-Hun Kang; Tianou Zhang; Yi-Fang Chu; Li Li Ji
Journal:  Eur J Appl Physiol       Date:  2015-08-20       Impact factor: 3.078

4.  Polyphenol content and modulatory activities of some tropical dietary plant extracts on the oxidant activities of neutrophils and myeloperoxidase.

Authors:  Cesar N Tsumbu; Ginette Deby-Dupont; Monique Tits; Luc Angenot; Michel Frederich; Stephane Kohnen; Ange Mouithys-Mickalad; Didier Serteyn; Thierry Franck
Journal:  Int J Mol Sci       Date:  2012-01-09       Impact factor: 6.208

5.  Misoprostol Inhibits Equine Neutrophil Adhesion, Migration, and Respiratory Burst in an In Vitro Model of Inflammation.

Authors:  Emily Medlin Martin; Rebecca Louise Till; Mary Katherine Sheats; Samuel L Jones
Journal:  Front Vet Sci       Date:  2017-09-28

6.  Avenanthramide supplementation attenuates exercise-induced inflammation in postmenopausal women.

Authors:  Ryan Koenig; Jonathan R Dickman; Chounghun Kang; Tianou Zhang; Yi-Fang Chu; Li Li Ji
Journal:  Nutr J       Date:  2014-03-19       Impact factor: 3.271

7.  Effects of Juglone on Neutrophil Degranulation and Myeloperoxidase Activity Related to Equine Laminitis.

Authors:  Ange Mouithys-Mickalad; Nazaré Storms; Thierry Franck; Justine Ceusters; Geoffroy de la Rebière de Pouyade; Ginette Deby-Dupont; Didier Serteyn
Journal:  Front Vet Sci       Date:  2021-07-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.